Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Read original at benzingaStocks · News reference
Why Is Natera Stock Gaining Tuesday?
Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's Ark Invest added to positions in Nvidia, Broadcom, and Intellia Therapeutics on Friday as these stocks declined. Nvidia exceeded earnings expectations with 106% revenue growth and raised guidance to 70% for fiscal 2028, now trading at 14x forward earnings. Broadcom is on track for accelerating growth with an upcoming earnings report. Intellia, a gene-editing biotech, has declined over 50% from recent highs but remains well-funded with analyst support.
Read original at the-motley-foolWhat’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Read original at benzingaMerck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
Read original at benzingaWhich Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.
Read original at the-motley-foolWhich Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.
Read original at the-motley-fool